Rheumatology Advance Access originally published online on June 22, 2004
Rheumatology 2004 43(9):1121-1128; doi:10.1093/rheumatology/keh277
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology Vol. 43 No. 9 © British Society for Rheumatology 2004; all rights reserved
Paper |
Anti-monocyte chemoattractant protein-1 gene therapy attenuates nephritis in MRL/lpr mice
1 Department of Medicine and Biosystemic Science, 2 Department of Medicine and Clinical Science, 3 Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, and 4 Laboratory for Genetics of Allergic Diseases, SNP Research Center, RIKEN Yokohama Institute, The Institute of Physical and Chemical Research (RIKEN), Kanagawa, Japan.
Correspondence to: H. Nakashima, Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan. E-mail: hnakashi{at}intmed1.med.kyushu-u.ac.jp
Objective. Monocyte chemoattractant protein-1 (MCP-1) is up-regulated and recruits and activates inflammatory cells in human diffuse proliferative lupus nephritis (DPLN) and in nephritis of lupus model MRL/lpr mice. The aim of this study was to examine whether anti-MCP-1 gene therapy inhibits the progression of nephritis in MRL/lpr mice.
Method. An NH2-terminal deletion mutant of the MCP-1 gene, 7ND, was injected into skeletal muscles of MRL/lpr mice with advanced stage nephritis to blockade MCP-1 and its receptor (CCR2) signalling pathway.
Result. Histological findings of kidneys in treated mice, which received more than four injections of 7ND, showed that protection against renal injury resulted from reduced infiltration of leucocytes. Therefore, this therapy has been shown to prolong the life span of MRL/lpr mice.
Conclusion. Anti-MCP-1 gene therapy is specifically effective in the localized inflammatory region. The data presented here indicate that this anti-MCP-1 gene therapy may be effective adjunct in the management of DPLN.
KEY WORDS: Monocyte chemoattractant protein-1 (MCP-1), Systemic lupus erythematosus (SLE), MRL/lpr mice, Diffuse proliferative lupus nephritis (DPLN), Gene therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M Schneider Exploring new territory: considering the future Lupus, March 1, 2007; 16(3): 221 - 226. [Abstract] [PDF]
|
|
|
|
 |
|
 M. C. Cid, M. P. Hoffman, J. Hernandez-Rodriguez, M. Segarra, M. Elkin, M. Sanchez, C. Vilardell, A. Garcia-Martinez, M. Pla-Campo, J. M. Grau, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis Rheumatology, November 1, 2006; 45(11): 1356 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Campbell, L. C. Burkly, H.-X. Gao, J. W. Berman, L. Su, B. Browning, T. Zheng, L. Schiffer, J. S. Michaelson, and C. Putterman Proinflammatory Effects of Tweak/Fn14 Interactions in Glomerular Mesangial Cells J. Immunol., February 1, 2006; 176(3): 1889 - 1898. [Abstract] [Full Text] [PDF]
|
|